Discloseable and connected transaction acquisition of the remaining 49.71% shareholding in a subsidiary involving the issue of consideration shares under Specific mandate; and proposed change of registered capital and amendments to the articles of association

Summary by 6ix AI

Suzhou Ribo Life Science Co. Ltd. has announced a transaction involving the acquisition of the remaining shareholding in a subsidiary, which will result in the company holding full ownership of that subsidiary. The transaction will be executed through a share swap, with consideration shares being issued to minority shareholders. The company will seek approval from independent shareholders for the transaction and the issuance of shares at an upcoming general meeting. This transaction is classified as both a discloseable and connected transaction under the relevant listing rules.

Written by 6ix AI from the company’s filing. How 6ix writes summaries